Ibuprofen And Pseudoephedrine Hcl Capsule, Liquid Filled
RxNorm Crosswalk NDC 58602-803

View RxNorm Concepts, RxCUIs, and Term Type mappings for this NDC

RxNorm Mapping Clinical Concepts

This drug is included in the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.

The product Ibuprofen And Pseudoephedrine Hcl (NDC 58602-803) is cross-mapped to the RxNorm terminology system to ensure clinical interoperability. This formulation is linked to a unique clinical concept (RxCUI 1299018). By anchoring Aurohealth Llc's product data to these standardized identifiers, healthcare systems can maintain accurate medication records, safely automate e-prescribing, and streamline pharmacy workflows.

The following clinical concept cards detail the semantic term types (TTY), prescribable names, and synonymous clinical strings as defined by the National Library of Medicine (NLM).

SCDPrescribable
Featured Concept

ibuprofen 200 MG / pseudoephedrine hydrochloride 30 MG Oral Capsule
(RxCUI 1299018)

Semantic Clinical Drug

Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.

Understanding RxNorm Mapping for Ibuprofen And Pseudoephedrine Hcl

RxNorm is a normalized naming system developed by the National Library of Medicine (NLM) to bridge the gap between different drug terminologies. By mapping NDC 58602-803 to RxCUI 1299018, this page provides the standardized "source of truth" required for hospital systems, e-prescribing software, and pharmacy benefit managers (PBMs) to communicate without errors.

Term Type (TTY) Legend for This Page

The clinical cards above utilize specific Term Types (TTY) to define the granularity of the drug concept:

  • PSN Prescribable Name: The standardized name preferred by electronic prescribing (eRx) applications for display.
  • SCD Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.

* Please review the full disclaimer at the bottom of this page.